Phenobarbitone-induced erythema multiforme-macular type in an 8-year-old child - a case report
DOI:
https://doi.org/10.66344/jpad.18.1.2008.568Keywords:
Phenobarbitone, erythema multiformeAbstract
Phenobarbitone is an antiepileptic known to cause skin reactions in 1 to 3% of patients. We report a case of erythema multiforme-macular type skin reaction in an 8-year-old female child that occurred immediately following administration of single dose phenobarbitone. The patient presented with confluent erythema with edema on both legs, dorsum of hands and face. The patient was treated symptomatically and given tab. prednisolone. The causal relationship between the drug was ‘probable’ and the severity ‘moderate [level 4(b)] and the preventability to be ‘not preventable’.References
Porter RJ, Meldrum BS. Antiseizure Drugs. In: Katzung BG (editor) Basic and Clinical Pharmacology, 8th edition, Boston Burr Ridge, Mc Graw Hill; 2000.
Magee P. Drug-induced skin disorders. In: Walker R, Edwards C, eds. Clinical Pharmacy and Therapeutics, 3rd edition. Philadelphia: Churchill Livingstone; 2003. p. 843-52.
Sweetman SC, ed. Martindale The Complete Drug Reference, 33rd edition. London: Pharmaceutical Press; 2002.
Pruksachatkunakorn C, Erythema multiforme. e-medicine. http://www.emedicine.com/derm/topic137.htm (accessed on 5th May, 2006).
Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
Elias SS, Patel NM, Cheigh NH. Drug-induced skin reactions. In: Dipiro JT, Talbert RL et al. eds. Pharmacotherapy A Pathophysiologic Approach, 5th edition. New York: McGraw-Hill; 2002.
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49: 2229-32.
Lau PM, Stewart K, Dooley MJ. Comment: hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2003; 37: 303-4.
Kumar P, Clark M, ed. Clinical Medicine, 5th edition. Edinburgh: WB Saunder; 2002.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.